Key facts
- This page summarizes Jaime Sepulveda's Form 4 filing for HilleVax, Inc. (HLVX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 17 Sep 2025, 16:30.
Jaime Sepulveda - 17 Sep 2025 Form 4 Insider Report for HilleVax, Inc. (HLVX)
- Reporting relationship
- Director
- Issuer ticker
- HLVX
- Reported as of
- 17 Sep 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Sep 2025, 16:30:04 UTC
- Prior SEC filing
- 25 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Bavier, Attorney-in-Fact for Jaime Sepulveda
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jaime Sepulveda filed Form 4 for HilleVax, Inc. (HLVX) on 17 Sep 2025.
Change
- Previous filing in this sequence was filed on 25 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001923444
Primary reporting owner
Sepulveda Jaime
- Relationship
- Director
- Address
- C/O HILLEVAX, INC., 321 HARRISON AVE, SUITE 500, BOSTON
- Signature
- /s/ Paul Bavier, Attorney-in-Fact for Jaime Sepulveda
- Signature date
- 17 Sep 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HLVX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -59,224
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 17 Sep 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Jaime Sepulveda is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
Footnote F2
Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.